ArticleOncotarget2016

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

Hojjat Ahmadzadehfar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.